Cellbyte with 2.75 million US dollar seed round

The Munich-based AI startup Cellbyte has raised 2.75 million US dollars in a seed financing round. The round was led by Frontline Ventures; other participants include Y Combinator, Pace Ventures, Saras Capital and Springboard Health Angels. The company intends to use the capital to expand its team, expand internationally and develop additional automated workflows for drug marketing.

Slow processes delay drug launch by months

Many processes in the pharmaceutical value chain remain time-consuming after the approval of a new active ingredient. Market access, pricing and HEOR teams have to compile extensive data from studies, evaluations and pricing sources. The fragmented data situation means that it often takes longer than a year for a new drug to reach the market. Pharmaceutical companies therefore spend considerable sums on external analyses and databases.

The success of a drug's entire life cycle is decided in the launch phase. Making the best decisions for the market launch requires insights from gigabytes of accurate, up-to-date information.

Felix Steinbrenner, Co-CEO and co-founder of Cellbyte

AI platform to bundle data streams and halve processes

This is exactly where Cellbyte comes in: The platform aggregates millions of data points from clinical studies, regulatory documents, HTA assessments, pricing structures and internal sources and analyzes them in real time using generative AI. This provides teams with robust decision-making aids for pricing strategies, approval documents and market access processes more quickly.

According to the company, workflows that previously took months can now be reduced to a fraction of the time using the platform, without compromising on quality.

Strong demand shortly after foundation

Cellbyte was founded in 2024 by Daniel Moreira, Felix Steinbrenner and Samuel Moreira. Just a few weeks after its launch, the start-up achieved a six-figure annual recurring turnover. It also signed its first contracts with major pharmaceutical companies such as Bayer. The start-up is expanding into international markets at the same time.

Financing supports scaling and team growth

With the new capital, Cellbyte plans to triple its workforce and expand the functionality of its AI platform. The aim is to establish itself as the globally preferred system for bringing new drugs to market.

Cellbyte is tackling one of the biggest problems in the pharmaceutical industry with an AI-supported strategy. Felix, Samuel and Daniel have been thinking globally from the start, and we are proud to support them in their expansion into the US...

William McQuillan, Partner at Frontline Ventures

Frontline Ventures partner William McQuillan emphasizes that Cellbyte addresses one of the key efficiency problems in the pharmaceutical industry. The three founders have both technological and pharmaceutical expertise and have been internationally oriented from the outset.